Welcome back, dear readers. I’ve missed you.
In case you failed to notice (I know…it’s highly unlikley), Pharma’s Cutting Edge has been absent from it’s usual rest stop along the information highway for the past week. The blog went down last Saturday morning. And when I say went down, I mean it was ransacked, hacked to bits. The [...]
A new crop of mega-pharma leaders has been installed recently, so it’s no surprise that they’re making rounds among analysts and reporters, telling anyone who will listen that they’ve seen the errors of their forebears’ ways and are committed to do things differently and better now. Chief among their messages is that they will tackle [...]
“Always do whatever’s next” – George Carlin (RIP)
I popped into the DIA Annual Mtg. for a day this week to chair a session on content reuse in clinical regulatory documents. Good turnout for the session and, as usual, for the meeting, which continues to be the one industry get-together that clinical-research worker bees are paid [...]
Above: NMR solution structure of exenatide from Ganfyd.org
taspoglutide advancement announcement
Lead 6 results press release
52-week data from Duration-1 trial
A bit more excitement than usual surrounded this year’s recently completed ADA annual meeting, with a flurry of news surrounding the GLP-1 mimetics and their brethren, the DPP-IV inhibitors.
In my mind, the most interesting bit of news concerned progress [...]
In December 2006, I described my initial impressions of Google Patent Search beta, a free USPTO patent search engine, powered by Google. As you’ll read, I wasn’t thrilled with this early release.
So, how has Google fared with some time–nearly 17 months–to marinate its patent search engine?
First off, Google hasn’t promoted the service out of beta yet. [...]
